LB PharmaceuticalsLBRX -1.97%12 Debt-to-Equity is 0.01 as of Mar. 2026. GuruFocus rates LBRX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 966 Biotechnology companies, LB Pharmaceuticals ranks better than 99.9% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for LB Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
LBRX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.84 Med: -0.01 Max: 0.01
Current: 0.01
During the past 4 years, the highest Debt-to-Equity Ratio of LB Pharmaceuticals was 0.01. The lowest was -0.84. And the median was -0.01.
LBRX's Debt-to-Equity is ranked better than 99.9% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs LBRX: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
LB Pharmaceuticals Debt-to-Equity Related Terms
LB Pharmaceuticals Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for LB Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LBRX vs MRVI, SLDB, JANX: Debt-to-Equity Comparison
For the Biotechnology subindustry, LB Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LB Pharmaceuticals Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LB Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where LB Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LB Pharmaceuticals (LBRX) has a Debt-to-Equity of 0.01 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on LB Pharmaceuticals and its competitors. According to the industry distribution chart, LB Pharmaceuticals ranks #1 out of 966 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is LB Pharmaceuticals' Debt-to-Equity too high?
LB Pharmaceuticals' current Debt-to-Equity is 0.01. The Biotechnology industry median Debt-to-Equity is 0.16. LB Pharmaceuticals' value of 0.01 is 93.8% below this industry median. Based on the distribution chart, LB Pharmaceuticals ranks #1 out of 966 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, LB Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LB Pharmaceuticals' Debt-to-Equity compare to MRVI and SLDB?
According to the Biotechnology industry distribution chart, LB Pharmaceuticals ranks #1 out of 966 companies for Debt-to-Equity. This places LB Pharmaceuticals in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. LB Pharmaceuticals' value of 0.01 is 93.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LB Pharmaceuticals's current Debt-to-Equity of 0.01 is 93.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on LB Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LB Pharmaceuticals's current Debt-to-Equity is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LB Pharmaceuticals stock overvalued right now?
LB Pharmaceuticals (LBRX) has a current Debt-to-Equity of 0.01. The current Debt-to-Equity is 0.01 and 93.8% below the Biotechnology industry median of 0.16. LB Pharmaceuticals' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For LB Pharmaceuticals (LBRX), the current Debt-to-Equity is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
12GF Score
Get the complete analysis for LBRX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LBRX has been successfully added to your 
